TDC
SLXP

Thompson Davis & Co’s SALIX PHARMACEUTICALS LTD DEL SLXP Stock Holding History

Thompson Davis & Co’s Portfolio SLXP Stock Details SLXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-1,915
Closed -$299K – 1358
2014
Q3 		$299K Buy
+1,915
New +$278K 0.39% 55
2014
Q1 		– Sell
-2,000
Closed -$180K – 910
2013
Q4 		$180K Buy
+2,000
New +$160K 0.27% 87

Other funds holding SLXP

PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VAM
Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Thompson Davis & Co's SLXP Position: Q4 2014 in Review

Thompson Davis & Co sold out of SALIX PHARMACEUTICALS LTD DEL (SLXP) in Q4 2014, closing a stake of 1,915 shares — an estimated $299K sold.

Thompson Davis & Co first reported a position in SLXP in Q4 2013 and held it in 2 quarters. The position peaked at $299K in Q3 2014. 346 funds tracked by Wall St. Rank hold SLXP as of Q4 2014.

  • Thompson Davis & Co reported no remaining SALIX PHARMACEUTICALS LTD DEL position as of Q4 2014 after selling out during the quarter.
  • Thompson Davis & Co sold 1,915 SALIX PHARMACEUTICALS LTD DEL shares in Q4 2014, an estimated $299K.
  • Thompson Davis & Co first reported a position in SALIX PHARMACEUTICALS LTD DEL in Q4 2013 and held it in 2 quarters.
  • Thompson Davis & Co's SALIX PHARMACEUTICALS LTD DEL position peaked at $299K in Q3 2014.
  • 346 funds tracked by Wall St. Rank held SALIX PHARMACEUTICALS LTD DEL as of Q4 2014.

Based on Thompson Davis & Co's 13F filing for Q4 2014, filed 6 Feb 2015.